Wentao Fu
Fujian Medical University(CN)Northeast Normal University(CN)Shanghai University of Traditional Chinese Medicine(CN)First Affiliated Hospital of Fujian Medical University(CN)Shuguang Hospital(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Metal complexes synthesis and properties, HER2/EGFR in Cancer Research
Most-Cited Works
- → A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication(2008)527 cited
- → FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia(2018)320 cited
- → FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1(2020)179 cited
- → Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-like Protease Inhibitors(2005)144 cited
- → FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer(2016)137 cited
- → FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy